175 related articles for article (PubMed ID: 8203052)
1. Immunocytochemically demonstrated expression of epithelial membrane antigen and carcinoembryonic antigen by exfoliated urinary cells in patients with bladder cancer.
Tanaka K; Takashi M; Miyake K; Koshikawa T
Urol Int; 1994; 52(3):140-4. PubMed ID: 8203052
[TBL] [Abstract][Full Text] [Related]
2. [Immunohistochemical localization of epithelial membrane antigen, carcinoembryonic antigen and secretory component in urinary bladder cancer].
Takashi M; Murase T; Mitsuya H; Koshikawa T; Nagura H; Haimoto H
Hinyokika Kiyo; 1986 Apr; 32(4):541-52. PubMed ID: 2426931
[TBL] [Abstract][Full Text] [Related]
3. Behavior of epithelial differentiation antigens (carcinoembryonic antigen, epithelial membrane antigen, keratin and cytokeratin) in transitional cell carcinomas of the bladder.
Sánchez-Fernández de Sevilla MC; Morell-Quadreny L; Gil-Salom M; Pérez-Bacete M; Fenollosa-Entrena B; Llombart-Bosch A
Urol Int; 1992; 48(1):14-9. PubMed ID: 1376008
[TBL] [Abstract][Full Text] [Related]
4. [Clinicopathological study of urinary bladder tumors. Clinical evaluation of immunohistochemistry in urine cytology].
Nagata Y; Kinoshita H; Kawamura N; Sasadaira S
Hinyokika Kiyo; 1985 Nov; 31(11):1931-7. PubMed ID: 4091136
[TBL] [Abstract][Full Text] [Related]
5. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
6. Enhanced detection of bladder cancer using the epithelial surface marker epithelial membrane antigen: a preliminary report.
Ring KS; Karp F; Benson MC
J Occup Med; 1990 Sep; 32(9):904-9. PubMed ID: 2074517
[TBL] [Abstract][Full Text] [Related]
7. Immunocytochemical analysis of prostate stem cell antigen as adjunct marker for detection of urothelial transitional cell carcinoma in voided urine specimens.
Cheng L; Reiter RE; Jin Y; Sharon H; Wieder J; Lane TF; Rao J
J Urol; 2003 Jun; 169(6):2094-100. PubMed ID: 12771726
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of urinary level of NMP22 as a diagnostic marker for stage pTa-pT1 bladder cancer: comparison with urinary cytology and BTA test.
Del Nero A; Esposito N; Currò A; Biasoni D; Montanari E; Mangiarotti B; Trinchieri A; Zanetti G; Serrago MP; Pisani E
Eur Urol; 1999 Feb; 35(2):93-7. PubMed ID: 9933801
[TBL] [Abstract][Full Text] [Related]
9. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
10. Enhanced expression of a tumor-cell-derived collagenase-stimulatory factor in urothelial carcinoma: its usefulness as a tumor marker for bladder cancers.
Muraoka K; Nabeshima K; Murayama T; Biswas C; Koono M
Int J Cancer; 1993 Aug; 55(1):19-26. PubMed ID: 8344748
[TBL] [Abstract][Full Text] [Related]
11. Epithelial membrane antigen as an immunohistochemical marker for transitional cell carcinoma of the urinary bladder.
Takashi M; Murase T; Kinjo T; Mitsuya H; Nagura H
Urol Int; 1987; 42(3):170-5. PubMed ID: 3303592
[TBL] [Abstract][Full Text] [Related]
12. Accuracy of the ImmunoCyt assay in the diagnosis of transitional cell carcinoma of the urinary bladder.
Feil G; Zumbrägel A; Päulgen-Nelde HJ; Hennenlotter J; Maurer S; Krause S; Bichler KH; Stenzl A
Anticancer Res; 2003; 23(2A):963-7. PubMed ID: 12820331
[TBL] [Abstract][Full Text] [Related]
13. Epithelial differentiation antigens and epidermal growth factor receptors in transitional cell bladder carcinoma: correlation with prognosis.
Nakopoulou L; Zervas A; Constantinides C; Deliveliotis C; Stefanaki K; Dimopoulos C
Urol Int; 1995; 54(4):191-7. PubMed ID: 7541921
[TBL] [Abstract][Full Text] [Related]
14. Effects of therapy on carcinoembryonic antigen activity in the urines of patients with cancer of the bladder.
James K; Alroy J; Miller AW; Flanagan M
Am J Clin Pathol; 1980 Feb; 73(2):250-3. PubMed ID: 6766663
[TBL] [Abstract][Full Text] [Related]
15. Cytokeratin 20 immunocytochemistry on urine sediments: A potential low-cost adjunct to cytology in the diagnosis of low-grade urothelial carcinoma.
Wadhwa N; Diwaker P; Lotha N; Arora VK; Singh N
Cytopathology; 2017 Dec; 28(6):531-535. PubMed ID: 28940433
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder.
Lekili M; Sener E; Demir MA; Temeltaş G; Müezzinoğlu T; Büyüksu C
Urol Res; 2004 May; 32(2):124-8. PubMed ID: 14685796
[TBL] [Abstract][Full Text] [Related]
17. BTA quantitative assay and NMP22 testing compared with urine cytology in the detection of transitional cell carcinoma of the bladder.
Casetta G; Gontero P; Zitella A; Pelucelli G; Formiconi A; Priolo G; Martinasso G; Mengozzi G; Aimo G; Viberti L; Tizzani A
Urol Int; 2000; 65(2):100-5. PubMed ID: 11025432
[TBL] [Abstract][Full Text] [Related]
18. Immunocytochemical staining for p53 and Ki-67 helps to characterise urothelial cells in urine cytology.
Courtade-Saïdi M; Aziza J; d'Aure D; Bérard E; Evrard S; Basset C; Lacoste-Collin L
Cytopathology; 2016 Dec; 27(6):456-464. PubMed ID: 27873391
[TBL] [Abstract][Full Text] [Related]
19. Urinary markers in the everyday diagnosis of bladder cancer.
Dal Moro F; Valotto C; Guttilla A; Zattoni F
Urologia; 2013; 80(4):265-75. PubMed ID: 24419920
[TBL] [Abstract][Full Text] [Related]
20. DD23 Biomarker: a prospective clinical assessment in routine urinary cytology specimens from patients being monitored for TCC.
Sawczuk IS; Pickens CL; Vasa UR; Ralph DA; Norris KA; Miller MC; Ng AY; Grossman HB; Veltri RW
Urol Oncol; 2002; 7(5):185-90. PubMed ID: 12644214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]